ストックスクリーナーアプリを入手
6.3804
6.42%
0.3854
前日終値:
$5.995
開ける：
$6.09
24時間の取引高:
114.79K
Relative Volume:
0.10
時価総額：
$884.74M
収益：
$170.28M
当期純損益:
$-225.25M
株価収益率:
-4.7973
EPS:
-1.33
ネットキャッシュフロー:
$-167.02M
1週間 パフォーマンス:
-0.93%
1か月 パフォーマンス:
-2.30%
6か月 パフォーマンス:
+89.32%
1年 パフォーマンス:
+33.75%
1日の値動き範囲:
$5.96
$6.45
1週間の範囲:
$5.91
$6.52
52週間の値動き範囲:
$2.28
$7.0665
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
名前
Adaptive Biotechnologies Corp
セクター
電話
206-659-0067
住所
1165 EASTLAKE AVE E, SEATTLE, WA
ADPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
6.385 | 884.74M | 170.28M | -225.25M | -167.02M | -1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.89 | 103.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.01 | 78.28B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
626.91 | 36.77B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.23 | 30.35B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
116.31 | 27.32B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-12-21 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | 開始されました | Credit Suisse | Underperform |
| 2022-06-03 | 開始されました | Piper Sandler | Neutral |
| 2022-02-16 | 繰り返されました | BTIG Research | Buy |
| 2022-02-16 | 繰り返されました | BofA Securities | Buy |
| 2022-02-16 | 繰り返されました | Goldman | Neutral |
| 2022-02-16 | 繰り返されました | JP Morgan | Overweight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-03-03 | ダウングレード | Goldman | Buy → Neutral |
| 2020-10-08 | 再開されました | BTIG Research | Buy |
| 2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-06-03 | 開始されました | Goldman | Buy |
| 2019-07-23 | 開始されました | BTIG Research | Buy |
| 2019-07-22 | 開始されました | BofA/Merrill | Buy |
| 2019-07-22 | 開始されました | Cowen | Outperform |
| 2019-07-22 | 開始されました | Goldman | Neutral |
| 2019-07-22 | 開始されました | Guggenheim | Buy |
| 2019-07-22 | 開始されました | William Blair | Outperform |
すべてを表示
Adaptive Biotechnologies Corp (ADPT) 最新ニュース
Geode Capital Management LLC Sells 20,450 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Drop in Short Interest - MarketBeat
Seattle InnoAdaptive's royalty financing I Changes at Tanium - The Business Journals
Barclays PLC Has $1.18 Million Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Stock Holdings Lifted by Barclays PLC - MarketBeat
Adaptive Biotechnologies Corporation Provides MRD Business Revenue Guidance for the Full Year 2024 - Marketscreener.com
State Street Corp Acquires 48,885 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Jane Street Group LLC - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) vs. Moderna (NASDAQ:MRNA) Financial Comparison - Defense World
BTIG Research Raises Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $9.00 - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.6%What's Next? - MarketBeat
Are Medical Stocks Lagging BellRing Brands (BRBR) This Year? - Yahoo Finance
Charles Schwab Investment Management Inc. Purchases 10,262 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
ADPT stock touches 52-week high at $6.71 amid robust gains By Investing.com - Investing.com South Africa
ADPT stock touches 52-week high at $6.71 amid robust gains - Investing.com
Jacobs Levy Equity Management Inc. Makes New $736,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Point72 Asset Management L.P. Makes New $2.54 Million Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Pier Capital LLC Grows Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions - Yahoo Finance
ADPT (Adaptive Biotechnologies) 10-Year Sortino Ratio : N/A (As of Dec. 06, 2024) - GuruFocus.com
ADPT (Adaptive Biotechnologies) 1-Year Sortino Ratio : 1.18 (As of Dec. 06, 2024) - GuruFocus.com
ADPT (Adaptive Biotechnologies) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies Corp (ADPT) With A Potential Upside Of More Than -193.16% - Stocks Register
Adaptive Biotechnologies (STU:1HM) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com
Matrix Capital Management Company LP Sells 10,922,590 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (FRA:1HM) Earnings Yield (Joel Gre - GuruFocus.com
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting - Yahoo Finance
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Short Interest Down 8.5% in November - MarketBeat
Adaptive Biotechnologies (STU:1HM) Operating Margin % : -70.27% (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies (STU:1HM) EPS (Diluted) : €-1.23 (TTM As of Sep. 2024) - GuruFocus.com
Cerity Partners LLC Boosts Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Rubric Capital Management LP Raises Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Massachusetts Financial Services Co. MA Lowers Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? - Benzinga
Millrace Asset Group Inc. Takes $1.40 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (FRA:1HM) Operating Margin % : -70.27% (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals (NASDAQ:TARS) versus Adaptive Biotechnologies (NASDAQ:ADPT) Financial Survey - Defense World
Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares - Investing.com India
Head to Head Comparison: Adaptive Biotechnologies (NASDAQ:ADPT) and Ginkgo Bioworks (NYSE:DNA) - Defense World
Adaptive Biotechnologies Corp: Is ADPT Stock Worth Buying? - Stocks Register
Short Interest in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Declines By 5.5% - Defense World
William Blair Has Bullish Forecast for ADPT FY2024 Earnings - MarketBeat
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Decrease in Short Interest - MarketBeat
Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know - Yahoo Finance
Rubric Capital Management LP's Strategic Acquisition in Adaptive Biotechnologies Corp - GuruFocus.com
Matrix Capital Management Reduces Stake in Adaptive Biotechnologies Corp - GuruFocus.com
Adaptive Biotechnologies (NASDAQ:ADPT) Trading Up 12.7% Following Analyst Upgrade - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Trading 12.7% Higher After Analyst Upgrade - MarketBeat
Adaptive Biotechnologies Corp (ADPT) 財務データ
収益
当期純利益
現金流量
EPS
1.15%
大文字化:
|
ボリューム (24 時間):